BioNTech Operating Margin vs. Shares Owned By Institutions
| BNTX Stock | USD 118.39 2.33 1.93% |
BioNTech Operating Profit Margin |
|
For BioNTech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioNTech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioNTech SE utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioNTech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioNTech SE over time as well as its relative position and ranking within its peers.
BioNTech |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.227 | Earnings Share (2.05) | Revenue Per Share 12.618 | Quarterly Revenue Growth 0.39 | Return On Assets (0.01) |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioNTech SE Shares Owned By Institutions vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioNTech's current stock value. Our valuation model uses many indicators to compare BioNTech value to that of its competitors to determine the firm's financial worth. BioNTech SE is rated third in operating margin category among its peers. It is rated below average in shares owned by institutions category among its peers producing about 1,229 of Shares Owned By Institutions per Operating Margin. At this time, BioNTech's Operating Profit Margin is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioNTech's earnings, one of the primary drivers of an investment's value.BioNTech Shares Owned By Institutions vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
BioNTech |
| = | 0.02 % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
BioNTech |
| = | 20.64 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
BioNTech Shares Owned By Institutions Comparison
BioNTech is currently under evaluation in shares owned by institutions category among its peers.
BioNTech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioNTech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioNTech will eventually generate negative long term returns. The profitability progress is the general direction of BioNTech's change in net profit over the period of time. It can combine multiple indicators of BioNTech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 244.8 M | 232.6 M | |
| Net Interest Income | 349.7 M | 367.2 M | |
| Interest Income | 357.6 M | 375.5 M | |
| Operating Income | 690.4 M | 655.9 M | |
| Net Income From Continuing Ops | 930.3 M | 883.8 M | |
| Income Before Tax | 1.2 B | 1.1 B | |
| Total Other Income Expense Net | 495.7 M | 520.5 M | |
| Net Income Applicable To Common Shares | 11.8 B | 12.4 B | |
| Net Income | 1.2 B | 1.1 B | |
| Income Tax Expense | 255.8 M | 243 M | |
| Change To Netincome | 1.4 B | 1.5 B | |
| Net Income Per Share | 3.83 | 3.64 | |
| Income Quality | 4.53 | 4.76 | |
| Net Income Per E B T | 0.78 | 0.80 |
BioNTech Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioNTech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioNTech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioNTech's important profitability drivers and their relationship over time.
Use BioNTech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.BioNTech Pair Trading
BioNTech SE Pair Trading Analysis
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BioNTech position
In addition to having BioNTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sports Thematic Idea Now
Sports
Companies in sporting activities arena as well as manufacturers of sporting goods and sport retailers. The Sports theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sports Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.